美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

亞盛醫藥

23.82

+0.62002.67%

盤後：23.820.00000.00%17:51 EST

成交量：4,886.00

成交額：11.68萬

市值：22.23億

市盈率：-12.03

高：24.69

開：24.26

低：23.72

收：23.20

52周最高：48.45

52周最低：17.56

股本：9,333.04萬

流通股本：7,158.28萬

量比：2.75

換手率：0.01%

股息：- -

股息率：- -

每股收益(TTM):-1.9795

每股收益(LYR):-0.7356

淨資產收益率：-159.65%

總資產收益率：-22.77%

市淨率：22.99

市盈率(LYR):-32.38

資料載入中...

總覽公司新聞資訊公告

亞盛醫藥盤中異動股價大漲6.42%報24.69美元

亞盛醫藥盤中異動股價大跌5.65%報23.21美元

亞盛醫藥BTK降解劑APG-3288新藥臨牀申請（IND）獲CDE許可，全球臨牀開發再提速

亞盛醫藥-B盤中升逾3% BTK降解劑1類新藥APG-3288片獲批臨牀

Bloomberg 專訪｜亞盛醫藥董事長楊大俊：聚焦未滿足臨牀需求，踐行全球化進階之路

亞盛醫藥楊大俊：不追風，走自己的路，讓產品説話

丁香园 Insight 数据库

2026年JPM大會諾華、阿斯利康、輝瑞等巨頭超百億美元交易頻現，中國資產成最大贏家

药厂那点事儿

JPM2026 | 亞盛醫藥：多元化管線建設取得突破性進展

医药魔方Info

亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段

港股異動 | 亞盛醫藥-B(06855)漲近4% BTK降解劑APG-3288新藥臨牀申請獲美國FDA許可

亞盛醫藥BTK降解劑APG-3288的新藥臨牀申請（IND）獲美國FDA許可

亞盛醫藥-B(06855)：David Sidransky將獲委任為首席獨立非執行董事

中金:維持亞盛醫藥-B(06855)「跑贏行業」評級 POLARIS-1歐美獲批

【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實

【直擊2025 ASH】亞盛醫藥耐立克®二線治療CML-CP臨牀研究數據更新，更前線治療潛力明顯

【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發，最佳MRD陰性完全緩解率超60%

亞盛醫藥的「底牌」

【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現

【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據

港股異動 | 亞盛醫藥-B(06855)升逾6% 耐立克®POLARIS-1研究獲美國FDA和歐洲EMA批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":23.82,"timestamp":1771016400000,"preClose":23.2,"halted":0,"volume":4886,"hourTrading":{"tag":"盘后","latestPrice":23.82,"preClose":23.82,"latestTime":"17:51 EST","volume":4,"amount":95.28,"timestamp":1771023062132,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.026724137931034526,"floatShares":71582800,"shares":93330405,"eps":-1.979486,"marketStatus":"總統日休市","change":0.62,"latestTime":"02-13 16:00:00 EST","open":24.255,"high":24.69,"low":23.72,"amount":116828.4444,"amplitude":0.04181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.979486,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":23.2,"preHourTrading":{"tag":"盘前","latestPrice":24,"preClose":23.2,"latestTime":"09:29 EST","volume":1717,"amount":41148.117908,"timestamp":1770992999094,"change":0.8,"changeRate":0.034483,"amplitude":0.237931},"postHourTrading":{"tag":"盘后","latestPrice":23.82,"preClose":23.82,"latestTime":"17:51 EST","volume":4,"amount":95.28,"timestamp":1771023062132,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.7510133203918645},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":71582800,"roa":"-22.77%","roe":"-159.65%","lyrEps":-0.735552,"volumeRatio":2.7510133203918645,"shares":93330405,"dividePrice":0,"high":24.69,"amplitude":0.04181,"preClose":23.2,"low":23.72,"week52Low":17.555,"pbRate":"22.99","psRate":"39.19","week52High":48.45,"institutionHeld":0,"latestPrice":23.82,"eps":-1.979486,"divideRate":0,"volume":4886,"delay":0,"ttmEps":-1.979486,"open":24.255,"prevYearClose":26.24,"prevWeekClose":23.82,"prevMonthClose":24.18,"prevQuarterClose":26.24,"fiveDayClose":24.52,"twentyDayClose":27.3,"sixtyDayClose":32.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"AAPG","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1764910800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2026-02-13","current":-12.033427,"percent":0.977186,"low":-76.454813,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"high":-12.826422,"avg":-32.23228,"sd":16.372548,"marketCap":2236446544.83},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94},{"date":"2025-04-17","current":-29.520055,"twenty":-34.225935,"median":-32.760201,"eighty":-30.07059,"marketCap":1639709582.7},{"date":"2025-04-25","current":-41.553435,"twenty":-35.045268,"median":-32.920123,"eighty":-30.119556,"marketCap":2311372741.24},{"date":"2025-05-02","current":-38.492689,"twenty":-35.554336,"median":-33.187028,"eighty":-30.682879,"marketCap":2146245101.28},{"date":"2025-05-09","current":-37.35919,"twenty":-36.170996,"median":-33.361942,"eighty":-30.776099,"marketCap":2093177176.92},{"date":"2025-05-16","current":-35.007117,"twenty":-35.955639,"median":-33.43308,"eighty":-31.102567,"marketCap":1969122395.28},{"date":"2025-05-23","current":-39.338512,"twenty":-36.352488,"median":-33.608398,"eighty":-31.19472,"marketCap":2213435510.22},{"date":"2025-05-30","current":-38.856398,"twenty":-37.35919,"median":-33.992043,"eighty":-31.242401,"marketCap":2192363417.29},{"date":"2025-06-06","current":-42.814884,"twenty":-37.865895,"median":-34.141844,"eighty":-31.758144,"marketCap":2419987007.19},{"date":"2025-06-13","current":-48.171029,"twenty":-38.492689,"median":-34.477812,"eighty":-31.846105,"marketCap":2722575737.57},{"date":"2025-06-20","current":-55.929302,"twenty":-38.862859,"median":-34.635358,"eighty":-32.113451,"marketCap":3154688383.5},{"date":"2025-06-27","current":-59.787237,"twenty":-39.399619,"median":-35.123604,"eighty":-32.336589,"marketCap":3381751544.24},{"date":"2025-07-03","current":-64.068526,"twenty":-41.436089,"median":-35.258863,"eighty":-32.429915,"marketCap":3624015684.35},{"date":"2025-07-11","current":-59.084566,"twenty":-43.897892,"median":-35.501693,"eighty":-32.48435,"marketCap":3338745741.38},{"date":"2025-07-18","current":-61.880278,"twenty":-48.308604,"median":-35.791073,"eighty":-32.545465,"marketCap":3494679880.36},{"date":"2025-07-25","current":-58.315576,"twenty":-54.849764,"median":-35.921968,"eighty":-32.616809,"marketCap":3304687864.64},{"date":"2025-08-01","current":-60.559654,"twenty":-57.422661,"median":-36.233253,"eighty":-32.655768,"marketCap":3410643633.03},{"date":"2025-08-08","current":-69.260076,"twenty":-59.023969,"median":-36.597865,"eighty":-32.679287,"marketCap":3910472388.03},{"date":"2025-08-15","current":-72.346957,"twenty":-59.602544,"median":-37.391167,"eighty":-32.709995,"marketCap":4086922647.44},{"date":"2025-08-22","current":-26.724459,"twenty":-60.097702,"median":-37.493155,"eighty":-32.679287,"marketCap":4314209810.62},{"date":"2025-08-29","current":-24.396919,"twenty":-59.865528,"median":-36.699167,"eighty":-32.48435,"marketCap":3966417985.85},{"date":"2025-09-05","current":-22.946281,"twenty":-59.664109,"median":-36.382297,"eighty":-31.979778,"marketCap":3724203040.4},{"date":"2025-09-12","current":-22.941741,"twenty":-59.475774,"median":-35.943012,"eighty":-31.122625,"marketCap":3735810338.07},{"date":"2025-09-19","current":-21.785524,"twenty":-59.316014,"median":-35.857966,"eighty":-29.943039,"marketCap":3550375801.58},{"date":"2025-09-26","current":-21.102028,"twenty":-59.062646,"median":-35.66937,"eighty":-29.751262,"marketCap":3428719452.06},{"date":"2025-10-03","current":-22.266298,"twenty":-59.025902,"median":-35.30284,"eighty":-28.699054,"marketCap":3625414266.5},{"date":"2025-10-10","current":-21.050291,"twenty":-58.738293,"median":-35.189473,"eighty":-26.732175,"marketCap":3423480133.18},{"date":"2025-10-17","current":-19.80269,"twenty":-58.191808,"median":-34.731922,"eighty":-24.468638,"marketCap":3221889328.22},{"date":"2025-10-24","current":-19.801335,"twenty":-57.904825,"median":-34.477812,"eighty":-23.569995,"marketCap":3222890223.42},{"date":"2025-10-31","current":-19.321494,"twenty":-57.532716,"median":-34.141844,"eighty":-22.943557,"marketCap":3150231208.59},{"date":"2025-11-07","current":-18.112503,"twenty":-56.69325,"median":-33.992043,"eighty":-22.558349,"marketCap":2949090425.48},{"date":"2025-11-14","current":-19.583345,"twenty":-55.920234,"median":-33.485756,"eighty":-22.342071,"marketCap":3199584585.23},{"date":"2025-11-21","current":-17.547753,"twenty":-55.765092,"median":-33.408485,"eighty":-22.122489,"marketCap":2860955000.96},{"date":"2025-11-28","current":-18.539078,"twenty":-55.318442,"median":-33.361942,"eighty":-21.796498,"marketCap":3034915066.08},{"date":"2025-12-05","current":-18.33416,"twenty":-53.27811,"median":-33.187028,"eighty":-21.590149,"marketCap":3005486168.49},{"date":"2025-12-12","current":-17.062052,"twenty":-48.796704,"median":-32.920123,"eighty":-21.073758,"marketCap":2802301628.68},{"date":"2025-12-19","current":-16.188794,"twenty":-48.517949,"median":-32.72391,"eighty":-20.125041,"marketCap":2665447409.6},{"date":"2025-12-26","current":-15.347054,"twenty":-48.514967,"median":-32.664532,"eighty":-19.801335,"marketCap":2537308174.25},{"date":"2026-01-02","current":-14.520508,"twenty":-48.239817,"median":-32.57809,"eighty":-19.656119,"marketCap":2406972911.39},{"date":"2026-01-09","current":-15.636938,"twenty":-46.480698,"median":-32.420873,"eighty":-19.300607,"marketCap":2595562368.02},{"date":"2026-01-16","current":-14.792082,"twenty":-45.997596,"median":-31.846105,"eighty":-19.073232,"marketCap":2461528990.12},{"date":"2026-01-23","current":-14.451393,"twenty":-45.706429,"median":-31.242401,"eighty":-18.892753,"marketCap":2402559084.95},{"date":"2026-01-30","current":-13.594278,"twenty":-43.897892,"median":-30.891003,"eighty":-18.486342,"marketCap":2268064814.82},{"date":"2026-02-06","current":-13.215954,"twenty":-42.7913,"median":-29.979764,"eighty":-18.329609,"marketCap":2208187061.91},{"date":"2026-02-13","current":-13.314281,"twenty":-42.590497,"median":-29.752899,"eighty":-18.136415,"marketCap":2236446544.83}],"updateTime":1771253293717},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611705143","title":"亞盛醫藥盤中異動 股價大漲6.42%報24.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611705143","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611705143?lang=zh_tw&edition=fundamental","pubTime":"2026-02-14 05:00","pubTimestamp":1771016411,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日05时00分，亚盛医药股票出现波动，股价大幅上涨6.42%。截至发稿，该股报24.69美元/股，成交量4603股，换手率0.00%，振幅2.31%。亚盛医药股票所在的生物技术行业中，整体涨幅为1.33%。其相关个股中，Moolec Science Sa、Aim Immunotech Inc.、Moolec Science Sa C/Wts 30/01/2028涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为6877.68%、357.46%、298.52%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Aim Immunotech Inc.，振幅分别为174.71%、80.59%、75.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260214050011a6f8e96b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","ASPHF","BK4139"],"gpt_icon":0},{"id":"2611359651","title":"亞盛醫藥盤中異動 股價大跌5.65%報23.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611359651","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611359651?lang=zh_tw&edition=fundamental","pubTime":"2026-02-13 04:56","pubTimestamp":1770929785,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日04时56分，亚盛医药股票出现异动，股价快速下挫5.65%。截至发稿，该股报23.21美元/股，成交量1257股，换手率0.00%，振幅3.17%。最近的财报数据显示，该股实现营业收入32.21百万美元，净利润-81.43百万美元，每股收益-0.95美元，毛利23.92百万美元，市盈率-11.45倍。亚盛医药股票所在的生物技术行业中，整体涨幅为0.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045625a49db8a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855","BK4139","ASPHF"],"gpt_icon":0},{"id":"2609095558","title":"亞盛醫藥BTK降解劑APG-3288新藥臨牀申請（IND）獲CDE許可，全球臨牀開發再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2609095558","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609095558?lang=zh_tw&edition=fundamental","pubTime":"2026-02-06 10:04","pubTimestamp":1770343440,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年2月6日 /美通社/ -- 致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，公司自主研发的原创新一代布鲁顿酪氨酸激酶靶向蛋白降解剂APG-3288的新药临床申请日前已获国家药品监督管理局药品审评中心许可，拟开发用于治疗复发/难治性血液系统恶性肿瘤。此前，该药物已获美国FDA许可开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4882324_ZH82324_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AAPG","LU2125909916.SGD","06855","BK4017","BK4129","LU1223082519.USD","BK1161","BK4139","APG","BK1574","BK4144","LU1223083913.SGD","CDE","LU1923622291.USD","LU1223082196.USD","TK","IND","LU2125909759.SGD"],"gpt_icon":0},{"id":"2608335305","title":"亞盛醫藥-B盤中升逾3% BTK降解劑1類新藥APG-3288片獲批臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335305","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608335305?lang=zh_tw&edition=fundamental","pubTime":"2026-02-04 11:08","pubTimestamp":1770174480,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B盘中涨超3%，截至发稿，股价上涨1.38%，报45.88港元，成交额3697.50万港元。公开资料显示，这是亚盛医药研发的新一代BTK靶向蛋白降解疗法。　　APG-3288是亚盛医药自主研发的首个新型高效和高选择性BTK降解剂。临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-04/doc-inhkrihn3096297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","LU1923622291.USD","BK1161","06855","AAPG","APG","LU2125909916.SGD","BK4129","LU2125909759.SGD","BK4139"],"gpt_icon":0},{"id":"2604030799","title":"Bloomberg 專訪｜亞盛醫藥董事長楊大俊：聚焦未滿足臨牀需求，踐行全球化進階之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2604030799","media":"亚盛医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604030799?lang=zh_tw&edition=fundamental","pubTime":"2026-01-19 08:40","pubTimestamp":1768783221,"startTime":"0","endTime":"0","summary":"第 44 届JPM会议日前在旧金山盛大召开。亚盛医药董事长、CEO 杨大俊博士，作为拥有近 20 年参会经历的行业见证者，日前接受全球知名财经媒体彭博社专访，分享了亚盛医药的全球化布局与行业发展趋势。亚盛医药已经启动了核心候选药物的多项全球 III 期临床研究，这是极少数中国biotech公司能做到的。亚盛医药已经成立 16 年。我们成功的关键就是聚焦全球未被满足的临床需求，坚持高质量研发，同时在中美两地同步推进临床项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119084610a43a8426&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119084610a43a8426&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK1161","BK1574","06855"],"gpt_icon":0},{"id":"2603379009","title":"亞盛醫藥楊大俊：不追風，走自己的路，讓產品説話","url":"https://stock-news.laohu8.com/highlight/detail?id=2603379009","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603379009?lang=zh_tw&edition=fundamental","pubTime":"2026-01-16 07:50","pubTimestamp":1768521048,"startTime":"0","endTime":"0","summary":"亚盛医药成立于 2009 年，16 年来一直深耕血液瘤领域。在日前举行的第 44 届摩根大通医疗健康年会上，亚盛医药共同创始人、董事长、CEO 杨大俊博士也受邀出席，在主会场就亚盛医药的战略布局、业务进展等发表演讲，引发国际同行的高度关注。成立以来，亚盛始终将血液肿瘤作为核心研究领域。亚盛始终坚守自身战略，不盲目跟随风向。相反，CDE 对这两款药物设定了非常严格的患者入组标准，以确保真正满足临床未满足的需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011608022297a202c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011608022297a202c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06855","06978","AAPG"],"gpt_icon":0},{"id":"2603937939","title":"2026年JPM大會諾華、阿斯利康、輝瑞等巨頭超百億美元交易頻現，中國資產成最大贏家","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937939","media":"药厂那点事儿","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937939?lang=zh_tw&edition=fundamental","pubTime":"2026-01-16 07:05","pubTimestamp":1768518317,"startTime":"0","endTime":"0","summary":"巨头交易频现，中国资产备受青睐。诺华公司周二下午宣布了一项针对中国生物技术公司泽璟生物的许可交易。再生元计划在2026年公布该药用于肥胖治疗的中国3期临床试验结果，并启动全球3期临床开发计划。截至2025年第三季度，19家大型制药公司现金储备总额超过1700亿美元，2025年前三季度产生了约1400亿美元的自由现金流，为大规模并购交易提供了充足的资金支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116070908a4c93942&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","09688","06855","BK1574","BK1161","01530","02268","ZLAB","BK1191","01477","AAPG","02615","02269","06978"],"gpt_icon":0},{"id":"2603386739","title":"JPM2026 | 亞盛醫藥：多元化管線建設取得突破性進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603386739","media":"医药魔方Info","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603386739?lang=zh_tw&edition=fundamental","pubTime":"2026-01-15 21:12","pubTimestamp":1768482720,"startTime":"0","endTime":"0","summary":"1月15日，亚盛医药在JPM大会上全面展示了公司2025年在产品商业化、全球临床开发、创新管线拓展及资本市场的里程碑进展，并对2026年的发展进行了展望。奥雷巴替尼2025年继续深化其全球化布局，一线治疗Ph+ ALL患者的全球注册III期临床获得FDA及EMA批准开展。亚盛医药的前沿技术转化与多元化管线建设已取得突破性进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115214635a4c7f403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115214635a4c7f403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","AAPG","BK1574","06855"],"gpt_icon":0},{"id":"2603621002","title":"亞盛醫藥精彩亮相第44屆摩根大通醫療健康年會主會場，「全球創新」戰略邁入新階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621002","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603621002?lang=zh_tw&edition=fundamental","pubTime":"2026-01-15 09:16","pubTimestamp":1768439760,"startTime":"0","endTime":"0","summary":"2025年是亚盛医药全球化布局提速的关键一年，我们在产品商业化、全球临床开发、管线创新、资本市场等多维度均实现跨越式突破。展望2026年，'全球创新'战略迈入新阶段，我们将继续以解决全球未满足的临床需求为核心，加速推进这些极具潜力的创新疗法，更好地惠及全球患者。在以患者为中心的全球创新战","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4864009_ZH64009_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0345770993.USD","IE00BLSP4452.SGD","LU0208291251.USD","LU2237443895.HKD","LU2746668974.SGD","IE00BJTD4N35.SGD","IE00BKDWB100.SGD","BK4516","LU0345770308.USD","LU2756315318.SGD","LU0942090050.USD","LU0868494617.USD","IE00BKVL7J92.USD","SG9999002224.SGD","IE0034235303.USD","LU0640476718.USD","06855","LU1668664300.SGD","LU2756315664.SGD","LU1280957306.USD","LU0106261372.USD","LU0265550946.USD","LU1551013425.SGD","AAPG","LU2211815571.USD","LU0820561818.USD","LU1267930490.SGD","LU1914381329.SGD","LU0689472784.USD","LU0211328371.USD","LU1974910355.USD","LABU","LU2592432038.USD","LU1894683348.USD","BK4585","LU1720051017.SGD","XBI","IE00BN8TJ469.HKD","LU0417517546.SGD","IE00BJLML261.HKD","LU2106854487.HKD","XLV","LU0215105999.USD","LU2381873111.SGD","LU0170899867.USD","LU1496350171.SGD","LU1629891620.HKD","LU0267386448.USD","BK4533","LU0345769631.USD"],"gpt_icon":0},{"id":"2601828013","title":"港股異動 | 亞盛醫藥-B(06855)漲近4% BTK降解劑APG-3288新藥臨牀申請獲美國FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828013","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828013?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 10:39","pubTimestamp":1767753579,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B(06855)涨近4%，截至发稿，涨3.69%，报53.4港元，成交额6164.18万港元。消息面上，1月7日，亚盛医药官微消息，公司宣布，原创新一代BTK靶向蛋白降解剂 APG-3288的新药临床申请(IND)已获美国FDA许可，将开展其治疗复发/难治B细胞恶性肿瘤的临床研究。这标志着公司在靶向蛋白降解领域的研发成果正式进入临床阶段，是亚盛医药全球创新管线的又一重大布局。该研究是一项全球多中心、开放性的I期临床研究，旨在评估APG-3288治疗复发/难治性血液系统恶性肿瘤患者的安全性、耐受性、PK特征及初步疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4139","BK4129","LU2125909916.SGD","AAPG","BK1574","LU2125909759.SGD","APG","06855","LU1923622291.USD"],"gpt_icon":0},{"id":"2601824845","title":"亞盛醫藥BTK降解劑APG-3288的新藥臨牀申請（IND）獲美國FDA許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824845","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824845?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 09:30","pubTimestamp":1767749400,"startTime":"0","endTime":"0","summary":"临床前研究结果显示，与其他在研BTK降解剂相比，APG-3288具更强的BTK降解能力、更高的选择性及更优越的PK特征，呈现潜力5。此次APG-3288的IND获美国FDA许可，是我们在这一领域的重大里程碑。我们将快速推进APG-3288的全球临床开发，积极探索蛋白降解剂这一新分子实体在血液肿瘤及其他BTK相关疾病中的治疗潜力，早日惠及更多患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4858031_ZH58031_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK4144","LU2125909916.SGD","APG","BK4139","BK1574","BK4129","IND","AAPG","LU1923622291.USD","BK1161","TK","LU2125909759.SGD"],"gpt_icon":0},{"id":"2595713529","title":"亞盛醫藥-B(06855)：David Sidransky將獲委任為首席獨立非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2595713529","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595713529?lang=zh_tw&edition=fundamental","pubTime":"2025-12-30 22:47","pubTimestamp":1767106065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，Debra Yu博士将获委任为董事会提名委员会新增成员，自2025年12月26日起生效。David Sidransky博士将获委任为首席独立非执行董事，自2025年12月26日起生效，以作为其他董事与本公司股东之间的中间人;及在与董事会主席或本公司管理层的正常沟通渠道不足的情况下，可与其他董事及本公司股东联络。研发委员会将由Marc E. Lippman, MD博士担任主席，由David Sidransky博士及王少萌博士担任成员。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","06855","BK4139","AAPG"],"gpt_icon":0},{"id":"2592466968","title":"中金:維持亞盛醫藥-B(06855)「跑贏行業」評級 POLARIS-1歐美獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2592466968","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592466968?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 11:38","pubTimestamp":1765942705,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持亚盛医药-B“跑赢行业”评级与目标价89港元，公司近期研发进展积极。耐立克一线治疗Ph+ ALL的全球III期研究已获欧美药监机构批准开展，并公布亮眼初步数据；利生妥针对高危基线人群亦显示出良好疗效与安全性，整体研发管线持续兑现，国际化稳步推进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2590316821","title":"【直擊2025 ASH】亞盛醫藥耐立克®治療TKI耐藥/不耐受CML-CP患者的註冊II期研究4年隨訪數據亮相，長期療效和安全性優勢再獲證實","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316821","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316821?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:45","pubTimestamp":1765244700,"startTime":"0","endTime":"0","summary":"此次展示的4年随访数据显示，耐立克在TKI耐药/不耐受的CML-CP患者中，持续展现出优于研究者决定的现有最佳可用疗法的显著疗效。值得关注的是，长期随访数据证实其安全性良好，血管闭塞事件发生率为7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842158_ZH42158_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ASH","BK4585","BK4588","LU1261432733.SGD","CP","06855","LU2463526074.USD","BK1161","BK4016","BK4109","BK4139","AAPG","BK1574"],"gpt_icon":0},{"id":"2590316824","title":"【直擊2025 ASH】亞盛醫藥耐立克®二線治療CML-CP臨牀研究數據更新，更前線治療潛力明顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316824","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316824?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:34","pubTimestamp":1765244040,"startTime":"0","endTime":"0","summary":"此次公布是对该研究在2024 ASH年会口头报告结果的持续更新，展现了更长时间的随访疗效与安全性特征。此次更新的研究结果进一步提示耐立克有望为二线CML-CP患者带来一种安全有效的治疗选择，尤其对那些一线使用二代BCR-ABL1酪氨酸激酶抑制剂治疗失败的患者。此次数据的更新，进一步体现了耐立克为更广泛的CML患者群体提供安全有效治疗选择的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842159_ZH42159_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","BK4139","ASH","LU1261432733.SGD","CP","BK1574","BK4588","BK1161","BK4016","LU2463526074.USD","BK4109","06855","AAPG"],"gpt_icon":0},{"id":"2590316827","title":"【直擊2025 ASH】亞盛醫藥耐立克®治療初治Ph+ ALL患者註冊III期研究（POLARIS-1）數據國際首發， 最佳MRD陰性完全緩解率超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590316827","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590316827?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 09:22","pubTimestamp":1765243320,"startTime":"0","endTime":"0","summary":"此次展示的POLARIS-1研究数据体现了耐立克在Ph+ ALL治疗领域的巨大潜力。数据显示，在诱导治疗3个周期内，耐立克联合低强度化疗在初治Ph+ ALL患者中的最佳微小残留病阴性率和MRD阴性完全缓解率分别为66.0%和64.2%；同时显示出良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4842157_ZH42157_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1161","BK4588","BK4134","06855","AAPG","LU1571399168.USD","ASH","BK4109","BK4533","BK4585","LU0985320562.USD","III","ALL","LU2463526074.USD","LU2355687059.USD","BK4107","LU1699723380.USD","BK4139"],"gpt_icon":0},{"id":"2590236472","title":"亞盛醫藥的「底牌」","url":"https://stock-news.laohu8.com/highlight/detail?id=2590236472","media":"药渡Daily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590236472?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 18:11","pubTimestamp":1765188681,"startTime":"0","endTime":"0","summary":"两大王牌产品的成功，成为亚盛医药快速成长的核心“底牌”。从血液肿瘤到实体瘤，从中国市场到全球舞台，亚盛医药更大的“底牌”正在翻开。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208214536a43b9611&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","BK4139","AAPG","06855"],"gpt_icon":0},{"id":"2589848384","title":"【直擊2025 ASH】亞盛醫藥Bcl-2抑制劑利生妥®治療維奈克拉經治髓系腫瘤患者的Ib/II期研究數據積極，全球競爭力持續顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848384","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848384?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 09:58","pubTimestamp":1765159080,"startTime":"0","endTime":"0","summary":"此次数据进一步验证了利生妥在恶性髓系肿瘤领域所具备的稳健疗效与良好安全性。利生妥是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。期待利生妥在未来，能为髓系恶性肿瘤治疗领域带来新的突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4841048_ZH41048_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","ASH","LU2463526074.USD","BK4109","BK4139","AAPG","06855"],"gpt_icon":0},{"id":"2589487292","title":"【直擊2025 ASH】突破BTKi耐藥和複雜核型的困境！亞盛醫藥口頭報告利生妥®中國關鍵註冊研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487292","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589487292?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 17:11","pubTimestamp":1765098660,"startTime":"0","endTime":"0","summary":"此项关键研究支持了利生妥于2025年7月获中国国家药品监督管理局批准上市。ASH年会是全球血液学领域规模最大的国际学术盛会之一，汇集了最前沿的研究进展及最新的药物研发数据，展示全球血液学领域的最高学术水平。目前，该药物已在中国获批上市，用于既往经过至少包含BTKi在内的一种系统治疗的成人CLL/SLL患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4840909_ZH40909_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4109","BK1161","BK4139","LU2463526074.USD","BK1574","AAPG","06855","ASH"],"gpt_icon":0},{"id":"2589519008","title":"港股異動 | 亞盛醫藥-B(06855)升逾6% 耐立克®POLARIS-1研究獲美國FDA和歐洲EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589519008","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589519008?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 09:33","pubTimestamp":1764898401,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B涨超6%，截至发稿，涨5.67%，报64.2港元，成交额1993.31万港元。消息面上，12月5日，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼联合化疗治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者的全球注册III期临床研究获美国食品药品监督管理局和欧洲药品管理局同意开展。作为耐立克在欧美监管机构获批的第二个全球注册III期研究，POLARIS-1研究在多国家多中心同步入组，将加速耐立克全球特别是欧美市场的上市进程。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","BK1574","06855","BK4139","BK4081","AAPG","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":49,"code":"91000000","status":"200"}]}}